Cardiff Oncology, Inc.
NASDAQ:CRDFBiotechnology
+$0.03 today
- Market cap
- $65.27M
- Beta
- 1.38
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.65
Volume 0.86M
Average 1.05M
CRDF Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Cardiff Oncology, Inc.NASDAQ: CRDF
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $221K fell 3.1% year over year, behind the +94.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.9% from the prior quarter. Over 3 fiscal years it compounded at +56.5% a year.
Context
- Depreciation & amortization amounted to 152.4% of revenue in FY2025, up 93.3 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -3.1% toward the trailing-twelve-month pace of +94.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 904K USD
- Year-over-year change
- +123.8%
- 4-year CAGR
- +19.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 904K | +123.8% |
| FY2024 | 2024-12-31 | 404K | +1.5% |
| FY2023 | 2023-12-31 | 398K | +68.6% |
| FY2022 | 2022-12-31 | 236K | -47.7% |
| FY2021 | 2021-12-31 | 451K | — |
Depreciation & Amortization vs competitors
How CRDF compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +94.7% is the 2nd highest of 9, against a peer median of +3.7%.
- Depreciation & amortization amounts to 196.6% of revenue for CRDF, versus a peer median of 25.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €5.09M EUR | +155.3% | -51.8% | 182.7% | |
| LTM Mar 2026 | $3.2M USD | -40.7% | +41.5% | — | |
| LTM Mar 2026 | CHF 2.61M CHF | +9.7% | -3.5% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $1.14M USD | -2.3% | +2.2% | — |
| LTM Mar 2026 | $1.03M USD | +94.7% | +56.5% | 196.6% | |
| LTM Mar 2026 | $810K USD | -21.4% | +18.0% | 25.6% | |
| LTM Mar 2026 | $248K USD | -57.2% | -46.1% | — | |
| LTM Mar 2026 | $143K USD | +37.5% | +8.6% | 8.0% | |
| LTM Mar 2026 | $70K USD | +62.8% | +21.1% | — | |
| Peer median (excluding CRDF) | — | +3.7% | +5.4% | 25.6% | |
Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 359K | 386K | 488K | 683K | 593K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 359K | 386K | 488K | 683K | 593K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 17.38M | 27.11M | 32.86M | 36.85M | 35.33M |
| Selling, General & Admin | 11.84M | 13.18M | 13.04M | 12.48M | 14.22M |
| Operating Expenses | 29.21M | 40.29M | 45.9M | 49.33M | 49.55M |
| Depreciation & Amortization | 451K | 236K | 398K | 404K | 904K |
| EBITDA | (27.84M) | (38.47M) | (41.04M) | (45.03M) | (44.95M) |
| EBITDA Margin | -7754.9% | -9965.8% | -8410.5% | -6592.5% | -7579.6% |
| Operating Income | (28.86M) | (39.9M) | (45.41M) | (48.65M) | (48.96M) |
| Operating Margin | -8037.6% | -10337.3% | -9305.7% | -7123.1% | -8256.3% |
| Interest Income | 264K | 1.58M | 4.07M | 3.26M | 3.1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 564K | 1.2M | 3.97M | 3.22M | 3.11M |
| Income Before Tax | (28.29M) | (38.7M) | (41.44M) | (45.43M) | (45.85M) |
| Pre-Tax Margin | -7880.5% | -10026.9% | -8492.0% | -6651.7% | -7732.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (28.29M) | (38.7M) | (41.44M) | (45.43M) | (45.85M) |
| Net Margin | -7880.5% | -10026.9% | -8492.0% | -6651.7% | -7732.0% |
| EPS (Basic) | (0.73) | (0.89) | (0.93) | (0.95) | (0.69) |
| EPS (Diluted) | (0.73) | (0.89) | (0.93) | (0.95) | (0.69) |
| Weighted Avg Shares | 39.03M | 43.6M | 44.68M | 47.65M | 66.84M |
| Weighted Avg Shares (Diluted) | 39.03M | 43.6M | 44.68M | 47.65M | 66.84M |
Cardiff Oncology, Inc.
NASDAQ:CRDF
Intrinsic Alpha fair value
Locked
Current Price
$0.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.